Exercise and fatigue in beta-thalassemia
Part of Blood & lymphatic clinical trials.
This study looks at why people with transfusion-dependent beta-thalassemia may feel tired or have trouble exercising. It compares patients with healthy volunteers matched by age and gender to understand the factors involved.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have beta-thalassemia (type B0 or B+) and need regular blood transfusions.
- You have been getting blood transfusions every 1 to 8 weeks for at least 5 years.
- You have not had a bone marrow transplant or a blood clot in the past.
- You are not participating in another interventional study during this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy that may help people with beta thalassemia who need regular blood transfusions. It aims to reduce or eliminate the need for transfusions by fixing the blood cell production problem.
This study tests if a breathing exercise device (incentive spirometer) can improve lung function and daily activity in children with thalassemia who receive regular blood transfusions. It aims to help them breathe easier and be more active.
This study tests an experimental medicine called YOLT-204 for people with beta-thalassemia who need regular blood transfusions. The goal is to see if this treatment is safe and if it might reduce the need for transfusions.
This study tests a special system (Hemanext One) that stores red blood cells with less oxygen, to see if it helps people with thalassemia who need regular transfusions. It may reduce side effects or improve how well the transfusions work.
This trial tests a one-time gene therapy using your own stem cells to help you produce healthy red blood cells and reduce or eliminate the need for regular blood transfusions. It is for people with transfusion-dependent beta-thalassemia who are between 3 and 35 years old.
This early study tests the safety and potential benefit of the LentiRed gene-based drug in people with transfusion-dependent beta-thalassemia (TDT) who are planning an autologous stem cell transplant. It may help reduce the severity of anemia, but the main goal at this stage is to check safety and side effects.
Hear when a new Beta Thalassemia Transfusion Dependent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.